Navigation Links
Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
Date:3/25/2009

TORONTO, March 25 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced that the 29th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium from March 24-27, 2009 will feature a key scientific symposium entitled, "The Role of Endotoxin", that will include presentations from six thought leaders in the field of sepsis. Presentations will include topics such as defining the role that endotoxin plays in sepsis and organ dysfunction; using Spectral's Endotoxin Activity Assay (EAA(TM)) to determine optimum management of patients with intra-abdominal infections; and, the role of diagnosing and treating endotoxemia in patients with severe sepsis and septic shock.

"The prominence given to endotoxin at this significant international conference reflects the increased recognition within the critical care community of its role in sepsis," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Results presented at this conference highlight the efficacy of our EAA(TM) in identifying patients most likely to benefit from anti-endotoxin therapies and the effectiveness of the Toraymyxin(TM) product to remove endotoxin and improve patient outcomes."

Spectral recently acquired the rights to Toraymyxin(TM) for the United States, where there is a significant unmet need for the approximately 100,000 patients that develop severe sepsis or septic shock each year. Additional information on the 29th International Symposium on Intensive Care and Emergency Medicine can be found at www.intensive.org.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral will seek FDA approval for Toraymyxin(TM) and intends to commercialize the product together with EAA(TM). Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces 2008 financial results
2. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
3. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
4. Spectral announces third quarter 2008 results
5. Spectral to bring anti-sepsis therapy to the U.S. market
6. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
7. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
8. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
11. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 Biocom, the association representing the ... a group of San Diego companies ... its 2016 Precision Medicine Advocacy Fly-In. Biocom Fly-In participants had ... Drug Administration (FDA), the Centers for Medicare and Medicaid Services ... San Diego U.S. Representatives Susan Davis and ...
(Date:2/11/2016)... 2016 Non-profit Consortium Aims to Generate ... Support Research and Discovery --> ... ambitious plan to sequence 100,000 individuals. It is intended to ... least 7 of North and East Asian countries. ... the project will focus on creating phased reference genomes for ...
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant announces ... "Stem Cell Research Products, Opportunities, Tools, and Technologies – ... The ... the stem cell industry, BioInformant has more than a ... stem cell market, by stem cell type. This powerful ...
Breaking Biology Technology:
(Date:2/9/2016)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... fourth quarter and year ended December 31, 2015.  ... of 2015 was $6.9 million, an increase of 61% compared to ... the fourth quarter of 2015 was $2.6 million compared to $0.2 ... --> --> Higher revenue and operating income in ...
(Date:2/4/2016)... The field of Human Microbiome research ... popular hubs of the biotechnology industry. While the ... of human microbiota, have garnered a lot of ... space has literally exploded in terms of both ... focuses on biomedical aspects of research, development, and ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
Breaking Biology News(10 mins):